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In addition to their role in protein degradation and digestion, proteases can also function as
hormone-like signaling molecules that regulate vital patho-physiological processes, includ-
ing inflammation, hemostasis, pain, and repair mechanisms. Certain proteases can signal
to cells by cleaving protease-activated receptors (PARs), a family of four G protein-coupled
receptors. PARs are expressed by almost all cell types, control important physiological and
disease-relevant processes, and are an emerging therapeutic target for major diseases.
Most information about PAR activation and function derives from studies of a few pro-
teases, for example thrombin in the case of PAR1, PAR3, and PAR4, and trypsin in the
case of PAR2 and PAR4. These proteases cleave PARs at established sites with the extra-
cellular N-terminal domains, and expose tethered ligands that stabilize conformations of
the cleaved receptors that activate the canonical pathways of G protein- and/or β-arrestin-
dependent signaling. However, a growing number of proteases have been identified that
cleave PARs at divergent sites to activate distinct patterns of receptor signaling and traf-
ficking. The capacity of these proteases to trigger distinct signaling pathways is referred
to as biased signaling, and can lead to unique patho-physiological outcomes. Given that a
different repertoire of proteases are activated in various patho-physiological conditions that
may activate PARs by different mechanisms, signaling bias may account for the divergent
actions of proteases and PARs. Moreover, therapies that target disease-relevant biased
signaling pathways may be more effective and selective approaches for the treatment
of protease- and PAR-driven diseases. Thus, rather than mediating the actions of a few
proteases, PARs may integrate the biological actions of a wide spectrum of proteases in
different patho-physiological conditions.
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INTRODUCTION
With over 800 members in mammals, G protein-coupled receptors
(GPCRs) are the largest family of cell-surface signaling proteins.
They are receptors for an extraordinary range of structurally
diverse agonists in the extracellular fluid, including endogenous
hormones, neurotransmitters, and paracrine regulators, as well as
multiple exogenous ligands (1, 2). Due to their critical importance
in the control of most patho-physiological processes, GPCRs are
the primary target for over 30% of the clinically used drugs (3,
4). The established mechanism of GPCR activation is that ago-
nist binding results in conformational changes in the receptor that
activate the Gα subunits of heterotrimeric G proteins, leading to
the dissociation of Gβγ dimers from Gα. Activated Gα and Gβγ
then initiate downstream signaling processes (5). To control the
duration and magnitude of this signaling, activated receptors are
phosphorylated by G protein-coupled receptor kinases (GRKs) or
other kinases, and then interact with β-arrestins, which mediate
Abbreviations: AP, activating peptide; APC, activated protein C; EPCR, endothelial
protein C receptor; ERK, extracellular signal-regulated kinase; F, coagulation fac-
tor; GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase;
MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinase; PAR,
protease-activated receptor; TF, tissue factor.
receptor desensitization and endocytosis (6). Depending on the
receptor and the agonist, internalized receptors are then sorted
to lysosomes for degradation, or move to the plasma membrane
for another cycle of activation (7, 8). However, a common fea-
ture of GPCRs is that a single receptor can interact with multiple
endogenous and exogenous ligands, each of which may activate the
receptor in different ways. For example, a large number of endoge-
nous opioid neuropeptides as well as many different opiate drugs
interact with opioid receptors, and different opioids and opiates
result in divergent processes of receptor activation and regulation
(9). Thus, the simplistic view of receptor activation and regula-
tion has been revised by the appreciation that different agonists of
the same receptor can result in distinct patterns of signaling and
regulation.
The early two-state model of receptor function suggested that
a receptor adopts active conformation upon ligand binding. This
model considered only one active state, leading to a single func-
tional readout. However, increased understanding of receptor
signaling has revealed that different ligands can initiate distinct
signaling events through the same GPCR. The heterogeneity of
signaling events by a single GPCR can include different maximum
responses from a single pathway (i.e., full or partial agonism) or
activation of distinctly different signaling pathways by different
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agonists. The capacity of different agonists to initiate signaling of
the same GPCR by distinct mechanisms is referred to as biased
agonism or signaling (10, 11), and has been described for many
GPCRs, including opioid receptors (12), angiotensin receptors
(13), and glutamate receptors (14). This phenomenon of signal-
ing bias is not surprising because GPCRs are flexible proteins that
interact with multiple ligands and regulatory proteins, all of which
may influence the capacity of the receptor to signal by particular
mechanisms. Indeed, recent advances in our understanding of the
structure of GPCRs in various activation states has revealed that a
single GPCR can exist in multiple active conformations that may
favor coupling to different signaling pathways (15, 16).
This review focuses on the capacity of different proteases and
synthetic ligands to induce biased signaling of protease-activated
receptors (PARs). The PARs are a family of four GPCRs (PAR1–4)
that belong to group A rhodopsin-like GPCR subfamily. The first
family member, PAR1, was identified as a receptor for thrombin,
a serine protease coagulation factor (17). PAR2 was subsequently
identified as a receptor for the serine protease trypsin (18), fol-
lowed by PAR3, another thrombin receptor (19), and PAR4, a
receptor for both thrombin and trypsin (20). PARs are expressed
in many tissues and cell types, where they regulate multiple patho-
physiological processes, including hemostasis, inflammation, pain,
cellular proliferation, and healing (21–23). However, in addition to
thrombin and trypsin, a large number of proteases have been iden-
tified that can cleave PARs. In some cases, these proteases cleave at
the same sites as thrombin or trypsin and thereby initiate common
signaling events. However, in other cases, proteases cleave PARs at
distinct sites, and either activate distinct signals (biased agonism),
or disarm the receptor by removing or destroying tethered ligand
domains (receptor antagonism). We will review mechanisms by
which various proteases and synthetic agonists activate PARs, and
will discuss the implications of protease-biased signaling of PARs
for patho-physiological control and therapeutic targeting.
MECHANISMS OF CANONICAL ACTIVATION AND
SIGNALING OF PARs
Unlike other GPCRs, the endogenous ligands for PARs reside
within the extracellular N-terminus of the receptors. Receptor
cleavage at the defined sites within the N-terminus by proteases
such as thrombin and trypsin reveals these tethered ligands that,
once exposed, can bind to regions in the second extracellular loops
of the cleaved receptors, initiating conformational changes in the
receptors that activate downstream signals (23). This is the canon-
ical mechanism of PAR activation (Figure 1A). There are subtle
differences in the mechanisms by which different proteases initi-
ate the canonical pathways of receptor activation, which depend
on the protease and PAR in question. For example, thrombin first
binds to PAR1 and PAR3; this action facilitates receptor cleav-
age and exposure of the tethered ligand sequence. Mutation of
the binding site reduces the efficacy with which thrombin acti-
vates these receptors, and mutation of the cleavage site prevents
FIGURE 1 | Mechanisms of canonical and biased PAR signaling.
(A) Canonical mechanisms of PAR signaling. Proteases such as trypsin
and thrombin cleave PARs at canonical cleavage sites, unmasking the
tethered ligand domain, which binds to the second extracellular loops of
the cleaved receptors. PARs that are activated by such mechanisms
often couple to multiple G protein-dependent and β-arrestin-dependent
signaling pathways. (B) Biased mechanisms of PAR signaling. Proteases
such as elastase, MMP1, and APC cleave PARs at sites distinct from the
canonical cleavage site. Cleavage may unmask a new tethered ligand
that could interact with domains in the cleaved receptor, leading to the
activation of unique and biased signaling pathways. (C) APs are synthetic
peptides that mimic the tethered ligands revealed by proteases that
cleave at canonical or biased sites. APs can activate the same pathways
as proteases, although tethered ligand and soluble peptides may also
trigger different signaling pathways and generate biased signal. (D)
Some proteases such as elastase that cleave PARs to not appear to
reveal tethered ligands, suggesting that proteolysis alone may activate
the receptor. (E) Proteolytic disarming of PARs. Proteases such as
cathepsin G cleave PARs and remove or destroy tethered ligands,
thereby disarming proteolytic activation.
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receptor activation (17, 19). On the other hand, trypsin activates
PAR2 directly, without first binding to the receptor (18, 24).
Accessory proteins can also influence the capacity of proteases to
activate PARs. In particular, proteins that anchor proteases to the
plasma membrane can enhance proteolytic activation. For exam-
ple, during tissue damage and inflammation, tissue factor (TF)
binds coagulation factors (F) VIIa, which in turn activates FX to
FXa. FXa and its co-factor FVa promote conversion of prothrom-
bin to thrombin, and subsequent PAR1 activation (25). Besides
promoting thrombin activation, FVIIa and FXa both can signal
directly through PAR1 and PAR2, although the efficiency and
potency of receptor activation is substantially enhanced when they
are coupled with TF (26). Similarly, the proteolytic activity of the
anticoagulant activated protein C (APC) toward PARs is largely
regulated by its association with the endothelial protein C receptor
(EPCR) at the surface of endothelial cells (27, 28).
Support for the tethered ligand mechanism of PAR activation is
provided by the observation that synthetic peptides, referred to as
activating peptides (APs), that mimic the tethered ligand domain
can also activate certain PARs directly, without the requirement for
proteolysis (Figure 1C). Peptides mimicking the tethered ligands
of PAR1, PAR2, and PAR4 can directly activate these receptors,
although with a considerably lower potency than the activating
proteases, especially in the case of PAR4 (17, 18, 20). The higher
EC50 values of APs compare to those of proteases possibly reflect
the differences between a tethered ligand and an untethered lig-
and in solution. PAR3 is not activated by tethered ligand-derived
peptides, and appears to be unable to signal directly, but rather
to serve as a co-factor for other PARs, such as PAR1 and PAR4
(29, 30).
Activating peptides have been considered to mimic the effects of
proteases and have been widely used to probe the functions of PARs
without the use of proteases, which can cleave multiple other pro-
teins that may influence outcomes. However, this is not always the
case because in some circumstances proteases and APs agonists can
exert different effects. For example, in human brain microvascular
endothelial cells, thrombin activation of PAR1 triggers endothe-
lial barrier permeability, whereas PAR1-AP (SFLLRN-NH2) has
no significant effect (31). In addition, the signaling properties
of a PAR2 mutant with substitutions within the trypsin-revealed
tethered ligand domain differ from those of APs with the same sub-
stitutions, suggesting distinct activation modes by tethered versus
soluble peptides (32). The divergent signaling effects of proteases
and APs provide evidence for biased signaling of PARs.
TISSUE-SPECIFIC COMPLEXITY AND DIVERSITY OF PAR
ACTIVATION AND SIGNALING
In addition to the diversity of signals that can originate from
the same receptor after activation by proteases or synthetic ago-
nists (i.e., biased signaling), many other factors also affect patho-
physiological outcome of PAR activation. These factors include
the availability of activated proteases as well as the existence of
regulatory and accessory proteins in different tissues and cell types.
The availability of active, functional proteases is a key require-
ment of PAR signaling, and the predominant endogenous pro-
teases that activate PARs may vary in different patho-physiological
states. For instance, the compliment of available active proteases
varies markedly during the course of inflammation and healing,
depending on the presence of immune cells, which are the source
of many proteases, and on the existence of endogenous inhibitors.
The compliment of proteases of mast cells, neutrophils, eosinophil,
and macrophages, which participate in different phases of inflam-
mation, varies considerably. For example, as the first responders
to microbial infection, neutrophil produce elastase, cathepsin
G, and proteinase-3 (33), whereas macrophages, which mediate
chronic inflammation, release plasmin, matrix metalloproteinases
(MMPs), and cathepsin S (34).
Although PARs can be activated by distinct proteases under
different conditions, proteases that cleave PARs at the same sites
would be expected to activate the same canonical signaling path-
way and to induce common patho-physiological outcomes. How-
ever, the consequences of PAR cleavage could vary considerably if
the activated proteases cleave PARs at distinct sites and are biased
agonists or even antagonists, as discussed below. Indeed, at any
one time multiple proteases would likely be activated and capable
of cleaving PARs at distinct sites with unique outcomes. Thus, the
active conformation of PARs may vary depending on the milieu of
available proteases, which may differ between health and disease
conditions. For example, during the initial stages of inflamma-
tory processes such as inflammatory bowel diseases or chronic
obstructive pulmonary disease, infiltration of neutrophils leads
to increased level of elastase (35, 36), a biased agonist of both
PAR1, and PAR2 (37, 38) (discussed below). Further complexity is
provided by the presence of endogenous protease inhibitors that
control the activity of proteases (39).
The outcome of PAR activation by the same protease or syn-
thetic agonist can also vary between tissues and cell types. For
example, thrombin and PAR1-AP cause relaxation of the intact
coronary artery but contraction when the endothelium is removed,
indicating distinct outcomes of PAR1 activation in endothelial ver-
sus vascular smooth muscle cells, possibility due to formation of
different signaling complexes (40).
MECHANISMS OF BIASED ACTIVATION AND SIGNALING OF
PARs
Compared to other GPCRs, the N-terminal domains of PARs are
particularly susceptible to proteolysis. Although the reasons for
this susceptibility are not fully understood, they probably relate to
the presence of protease binding sites on the receptors, the exis-
tence of multiple scissile bonds, and the lack of groups that would
sterically hinder proteolysis. However, the outcome of PAR activa-
tion depends on the site of proteolytic cleavage. Those proteases
that cleave PARs at the conserved activating sites reveal tethered
ligands that trigger the canonical signaling pathways (Figure 1A).
Proteases that cleave PARs at distinct sites can act as biased agonists
by triggering signals that are distinct from those activated by the
canonical pathways (Figures 1B,D). In some cases, these alterna-
tive signaling mechanisms appear to involve exposure of distinct
tethered ligands (Figure 1B). However, in other instances recep-
tor cleavage per se may generate a conformational change that is
sufficient to activate the receptor (Figure 1D). Alternatively, pro-
teases can destroy or remove tethered ligand domains, forming
N-terminally truncated receptors that are unresponsive to further
activation by other proteases (Figure 1E).
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Table 1 | Activation of PAR1 by different proteases, their cleavage sites, synthetic activating peptide sequence, signaling pathways, and
physiological effects.
Receptor Protease Cleavage site Activating peptide Signaling pathways Physiological response Reference
PAR1
Thrombin Platelet aggregation,
endothelial barrier disruption,
vascular smooth muscle cells
proliferation
(17, 41, 42)
Canonical
cleavage
Factor Xa 38LDPR↓SFLL45 SFLLRN-NH2 Gαq/Ca2+,
Gα12/13-Rho,
β-arrestin/ERK1/2
Pro-inflammation, endothelial
barrier protection, inhibition of
cancer cell migration,
fibroblast proliferation
(43–45)
Plasmin Platelet activation and
deactivation (by non-specific
cleavage)
(46)
MMP1 36ATLD↓PRSF43 PRSFLLRN-NH2 Gα12/13-Rho, MAPK Platelet thrombogenesis and
clot retraction, disruption of
barrier function, matrix
remodeling, vascular
angiogenesis
(47–49)
MMP13 39DPRS↓FLLR46 Not studied Gαq/Ca2+, ERK1/2 Participate in β-AR over
activation-dependent cardiac
dysfunction
(50)
Non-canonical
cleavage
Elastase 42SFLL↓RNPN49 RNPNDKYEPF-NH2 Gαi/MAPK Stress fiber formation and
endothelial barrier
permeability
(37)
APC 43FLLR↓NPND50 NPNDKYEPF-NH2 β-arrestin/Rac1, Akt Cytoprotective, endothelial
barrier protection
(51–54)
Proteinase-3 33ATNA↓TLDP40 TLDPRSF-NH2 Gαi/MAPK Stress fiber formation and
endothelial barrier
permeability
(37)
Other
proteases
Granzyme K N.D. N.D. ERK1/2, p38 MAPK Cytokine secretion and
fibroblast proliferation
(55)
Activated PARs can couple to multiple G protein-dependent
(Gαq, Gα12/13, Gαi, Gαs, and Gβγ) and β-arrestin-dependent
pathways. Although in many instances a particular protease or
synthetic agonist can activate more than one of these pathways,
in some cases proteases and synthetic agonists activate a single
pathway. By comparing and categorizing the signaling pathways
that are initiated by different proteases and synthetic agonists
with the overall outcome of receptor activation, it is possible
to identify the primary signaling pathways responsible for PAR-
mediated patho-physiological responses (Tables 1–3). Moreover,
a comprehensive understanding of the mechanisms and out-
comes of PAR signaling by different proteases and synthetic ago-
nists can guide the development of agonists and antagonists that
may selectively activate or inhibit disease-relevant pathways. This
approach has implications for development of pathway-specific
therapies.
PAR1 ACTIVATION AND SIGNALING
CANONICAL ACTIVATION OF PAR1
As the first identified PAR, the canonical mechanisms of PAR1
activation and signaling have been extensively investigated. An
interaction between thrombin’s anion-binding exosite I and a neg-
atively charged region in the extracellular N-terminus of PAR1
(51DKYEPF56) increases the affinity of thrombin for the recep-
tor and facilitates cleavage (17). Binding of thrombin enables the
enzyme to cleave the receptor at position R41/S42, which reveals the
tethered ligand domain beginning with SFLLRN in human PAR1,
and initiates downstream signaling cascades (Figure 2). After
cleaving PAR1, thrombin may remain associated with the receptor
to facilitate its action on other thrombin receptors, such as PAR4
(83). Thrombin-activated PAR1 can trigger multiple G protein-
dependent and -independent signaling pathways, including Gαq,
Gαi, and Gα12/13. A region spanning the thrombin cleavage sites
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Table 2 | Activation of PAR2 by different proteases, their cleavage sites, synthetic activating peptide sequence, signaling pathways, and
physiological effects.
Receptor Protease Cleavage site Activating peptide Signaling pathways Physiological response Reference
PAR2
Trypsin Pro-inflammation, induction of
hypotension, mechanical and
thermal hyperalgesia, cardio
protective (reduced infarct size)
(42, 56–58)
Canonical
cleavage
Tryptase 33SKGR↓SLIG40 SLIGKV-NH2 Gαq/Ca2+,
Gα12/13-Rho, MAPK
ERK1/2, β-arrestin, Akt,
Gαi and Gαs/cAMP
Pro-inflammatory and
hyperalgesia; increase
paracellular permeability of
intestine; mast cell
degranulation; cell proliferation
(59–61)
Factor VIIa Cancer cells migration and
invasion
(62)
Factor Xa Cancer cells migration and
invasion
(62)
KLKs Cell proliferation (63, 64)
Elastase 64FSAS↓VLTG71 Not active Rho/ERK1/2 N.D. (38, 65)
Non-canonical
cleavage
Proteinase-3 57VFSV↓DEFS64 Not active N.D. N.D. (38)
Cathepsin G 61VDEF↓SASV68 Not active N.D. N.D. (38, 65)
Cathepsin S 53VTVE↓TVFS60 TVFSVDEFSA-NH2 Gαs/cAMP Pro-inflammatory, visceral
hyperalgesia, itch
(66–69)
Other
proteases
Gingipain-R N.D. N.D. Gαq/Ca2+, ERK1/2 Activate human gingival
fibroblasts and modulate
immune response
(70)
KLK 14 N.D. N.D. Gαq/Ca2+, ERK1/2 Colon tumorigenesis,
pro-inflammatory
(71)
act as a “hot spot” for many proteases, including granzyme A, plas-
min, and FXa, that cleave at the same site as thrombin and trigger
similar cellular responses (Table 1). Proteases that cleave at other
sites can induce biased signaling of PAR1.
BIASED ACTIVATION OF PAR1
Several proteases have been identified that cleave PAR1 at sites
different from the canonical thrombin site, leading to distinct
patho-physiological outcomes.
Activated protein C
Activated protein C is a natural anticoagulant with powerful
anti-inflammatory and cytoprotective activities (84). In many
cases, APC exerts its protective effect via EPCR and PARs. On
the surface of endothelial cells, binding of protein C to EPCR
promotes its activation by thrombin, and EPCR-bound APC in
turn exerts its cytoprotective effect by cleaving and activating
PAR1 (51). Different from thrombin-mediated PAR1 activation,
APC activation of PAR1 requires colocalization of PAR1 with
EPCR in caveolae microdomains in the form of a signaling com-
plex with caveolin-1 (85, 86). Besides subcellular localization, the
differential PAR1-dependent cellular responses induced by throm-
bin and APC may also be explained by their distinct cleavage
sites. APC cleaves PAR1 at the canonical cleavage site R41/S42,
as well as at an alternate site R46/N47, with the latter being the
primary cleavage site that is responsible for its cytoprotective
effect (51, 52) (Figure 2). A synthetic AP corresponding to the
tethered ligand that would be revealed by this alternate cleavage
(N47PNDKYEPFWEDEEKNESGL66-NH2) mimics the protective
effects of APC both in vitro and in vivo. Cleavage of PAR1 at
R46/N47 by APC leads to β-arrestin 2-mediated Rac1-activation
independent of G protein (53). Both APC and its AP stimulate
PAR1-dependent phosphorylation of glycogen synthase kinase 3
β and Akt (51). In contrast to thrombin-activated PAR1, APC-
cleaved PAR1 fails to activate extracellular signal-regulated kinase
(ERK)1/2. Thus, APC and thrombin cleave PAR1 at different sites
leading to the exposure of distinct tethered ligand agonists that
activate different signaling pathways.
Matrix metalloproteinases
Matrix metalloproteinases are a family of 28 zinc-dependent
proteases that play important roles in regulating platelet and
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Table 3 | Activation of PAR3 and PAR4 by different proteases, their cleavage sites, synthetic activating peptide sequence, signaling pathways,
and physiological effects.
Receptor Protease Cleavage site Activating peptide Signaling
pathways
Physiological response Reference
PAR3 Canonical
cleavage
Thrombin 35LPIK↓TFRG42 TFRGAP-NH2 (for
PAR1 and PAR2)
ERK1/2 IL-8 production (19, 72, 73)
Non-canonical
cleavage
APC 38KTFR↓GAPP45 GAPPNSFEEFPFS N.D. Cytoprotective (27, 74)
PAR4 Canonical
cleavage
Thrombin Platelet activation and
aggregation; platelet
endostatin release
(75–77)
Trypsin 44PAPR↓GYPG51 GYPGQV-NH2 Ca2+ Neutrophil recruitment (78)
Plasmin Platelet activation and
aggregation
(79, 80)
Cathepsin G Platelet activation and
aggregation
(81)
Other
proteases
MASP1 N.D. N.D. Ca2+ NF-kB, p38
MAPK
N.D. (82)
FIGURE 2 | PAR1 N-terminus with major cleavage sites identified.
N-terminus of human PAR1 (1–114). The residues in red denote the
canonical tethered ligand and a corresponding AP that is revealed by
thrombin cleavage. The cleavage sites for different proteases and the
corresponding AP for each protease are indicated in the boxes. Gray
shading represents membrane.
endothelial function (87). Two human MMPs, MMP1 and
MMP13, and one murine MMP, MMP1a, exhibit activity toward
PAR1. Both MMP1 and MMP13 cleave PAR1 at non-canonical
sites (D39/P40 for MMP1, S42/F43 for MMP13, Figure 2), which
either generate an extended tethered ligand with two more
amino acids or a truncated tethered ligand lacking the first
serine residue compared to the tethered ligand exposed by
thrombin (Figure 2). Similar to thrombin, MMP1-cleaved PAR1
activates the Gα12/13-Rho-GTPase pathway, and also leads to
mitogen-activated protein kinase (MAPK) signaling and platelet
shape changes (47). However, MMP1-activated PAR1 is a weak
agonist of Ca2+ signaling and platelet aggregation (47, 48). The
biased cellular response between thrombin- and MMP1-activated
PAR1 has also been studied in vascular smooth muscle cells.
Thrombin activation of PAR1 leads to a supercontractile, differ-
entiated phenotype that is pertussis toxin-sensitive, suggesting the
involvement of Gαi activation, whereas MMP1 activation of PAR1
results in a dedifferentiated phenotype via a Gαi-independent
mechanism (49). These differences in signaling in vascular smooth
muscle cells may account for the opposite effects of thrombin and
MMP1 on the development of arterial stenosis following arterial
injury (49).
Whereas MMP1 is mostly expressed in vascular endothe-
lial cells, platelets, and macrophages, MMP13 is prominently
expressed in cardiac fibroblasts and cardiomyocytes. Expression
of MMP13 is increased in cardiac fibroblasts after β2-adrenergic
receptor activation (50). MMP13 cleaves PAR1 one amino acid
downstream from the thrombin site at S42/F43. In ventricular
myocytes of neonatal rats, MMP13-activated PAR1 leads to phos-
phorylation of ERK1/2 and p38 MAPK. However, when compared
to thrombin, MMP13 elicits similar levels of ERK1/2 activation but
only modestly stimulates inositol phosphate formation (50). Due
to the close proximity of the thrombin and MMP13 cleavage sites,
it is likely that MMP13 activates PAR1 by a tethered ligand mech-
anism. Whether this single amino acid difference in the tethered
ligands is sufficient to generate biased signaling of PAR1 remains
to be determined.
Neutrophil proteases
During acute inflammation, neutrophils are the first cells infil-
trate to the inflammatory site and are important mediators of
inflammatory response. Elastase and proteinase-3 are stored in
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large quantities within secretory granules and are activated and
released into the extracellular environment during inflammation
(88). Recent studies show that both proteases are biased agonists
for PAR1 (37). Elastase cleaves PAR1 at L45/R46, and proteinase-3
cleaves PAR1 at A36/T37 (Figure 2). Similar to thrombin, elastase
and proteinase-3 activate PAR1 via tethered ligand mechanism. In
contrast to thrombin-cleaved PAR1, which activates Gα12/13- as
well as Gαq-mediated signaling pathways, elastase, proteinase-3
and their corresponding APs (elastase-AP: RNPNDKYEPF-NH2;
proteinase-3-AP: TLDPRSF-NH2) induce Gαi-mediated MAPK
activation, regardless of their distinct cleavage positions. Although
proteinase-3 cleaves prior to canonical activation site (five amino
acids N-terminal to the thrombin cleavage site), proteinase-3 fails
to induce Ca2+ signaling, suggesting the possibility that the extra 5
residues (TLDPR) may has an inhibitory role in coupling activated
PAR1 to Gαq and Ca2+ mobilization (37).
PAR1 ACTIVATION BY SYNTHETIC LIGANDS
Several synthetic APs corresponding to the tethered ligands
exposed by proteolytic activation of PAR1 have been evaluated
in vitro or in vivo. These include AP corresponding to tethered
ligands revealed by thrombin (SFLLRN-NH2), neutrophil elas-
tase (RNPNDKYEPF-NH2), neutrophil proteinase-3 (TLDPRSF-
NH2), MMP1 (PRSFLLRN-NH2), and APC (NPNDKYEPF-NH2)
(Figure 2). Since these proteases cleave PAR1 between residues 35
and 45, the APs share considerable homology. For example, the
thrombin and MMP1 APs differ by only two amino acids, whereas
the APC AP is only one amino acid shorter than the elastase-
AP. However, regardless of their sequence homology, different APs
display considerable signaling bias. For instance, the thrombin AP
SFLLRN-NH2 activates Gαq-mediated signaling (89), whereas the
MMP1 AP PRSFLLRN-NH2 is a weak agonist of Gαq signaling
and preferentially activates the Gα12/13 pathway (47). In addition,
elastase-AP RNPNDKYEPF-NH2 stimulates ERK1/2 phosphory-
lation via Gαi but the APC AP NPNDKYEPF-NH2 activates ERK
by a β-arrestin-dependent but G protein-independent mechanism
(37, 51).
The differences in AP-induced signals lead to distinct physio-
logical outcomes. For example, in human umbilical vein endothe-
lial cells, elastase-AP and APC-AP suppress thrombin-stimulated
increase in endothelial barrier permeability, whereas proteinase-
3-AP and MMP1-AP have the opposite effect (37).
Other structurally distinct synthetic peptides can also activate
PAR1. YFLLRNP-NH2, a peptide that differs from the thrombin
AP by a single amino acid, is able to cause platelet shape changes by
a Ca2+-independent mechanism (90) that may involve Gα12/13-
dependent activation of Rho kinase (91). TFRRRL-NH2, a peptide
derived from the C-terminus of P2Y receptor, can activate PAR1
on human platelets and stimulate Gα12/13- and Gαq-dependent
changes in platelet shape and aggregation (92).
In addition to providing evidence for the capacity of PARs to
exhibit signaling bias, studies of APs signaling have also provided
insights into the molecular mechanisms of PAR1 activation. Thus,
the thrombin AP SFLLRN-NH2 is able to activate both Gαq and
Gα12/13 pathways, with a preference for Gαq, whereas the MMP1
AP PRSFLLRN and YFLLRNP activate only Gα12/13 signals (47).
These observations suggest the importance of the serine residue
at position 1 of the peptide for Gαq activation, whereas either
replacing it with another residue or extending the peptide with
additional N-terminal residues both result in a reduction in Gαq
activation. The precise mechanisms of how these peptides interact
with cleaved PAR1 to induce these divergent signals remains to be
determined.
PAR2 ACTIVATION AND SIGNALING
CANONICAL ACTIVATION OF PAR2
The canonical mechanism of activation of PAR2 by trypsin
involves hydrolysis at position R36/S37, which reveals the tethered
ligand SLIGKV (human) (24) or SLIGRL (mouse) (18) (Figure 3).
This exposed tethered ligand then interacts with the second extra-
cellular domain of the cleaved receptor and trigger multiple G
protein-dependent and -independent signaling pathways (93).
Trypsin-activated PAR2 leads to the activation of Gαq-mediated
Ca2+ mobilization (94), Gαs-dependent formation of cAMP (95),
Gα12/13-mediated increasing in Rho-Kinase activity (95), recruit-
ment of β-arrestin-1 and -2 (96), ERK1/2 phosphorylation (97,
98), and subsequent receptor internalization and degradation
(94, 99).
Several other proteases cleave PAR2 at the canonical site
(Table 2). Serine proteases that activate canonical PAR2 signal-
ing include trypsin I/II (18, 94), trypsin IV (100, 101), tryptase
(59, 102), coagulation factors VIIa and Xa (26), acrosin (103),
granzyme A (104), and kallikrein 2, 4, 6, and 14 (63, 64, 105).
Proteases that cleave PAR2 at the canonical activation site would
be expected to reveal the conserved tethered ligand domain and
to activate the same compliment of signaling pathways as trypsin.
Despite the fact that these proteases cleave PAR2 at the same site as
trypsin, the potency with which they activate PAR2 shows consid-
erable variability. This variability may be due to different rate and
efficiency of cleavage between different proteases. Although not
all the Kcat values for proteases cleaving PAR2 have been reported,
published in vitro peptide proteolytic assays show marked differ-
ences in the kinetics of cleavage. Cleavage at sites that disable the
receptor may also contribute to the variable potency of proteases-
mediated signaling. Compared to trypsin, tryptase is a partial
agonist of PAR2-dependent Ca2+ signaling, which may be related
to a second cleavage site at R41/S42, which would deactivates the
receptor and limit its potential to induce further Ca2+ signals
(102). Post-translational modification of PARs may also affect
their susceptibility to proteolytic activation. Although mast cell
tryptase can activate PAR2, its ability to do so is limited by recep-
tor glycosylation, which presumably sterically hinders hydrolysis at
R36/S37 (106). Other proteases such as kallikrein-related peptidase
14 and gingipain-R have been shown to signal by PAR2-dependent
mechanism, although the cleavage sites need to be confirmed
(70, 71).
BIASED ACTIVATION OF PAR2
As is the case for PAR1, several proteases have been identified that
cleave PAR2 at distinct sites, leading to signaling bias.
Neutrophil proteases
Neutrophil elastase, proteinase-3, and cathepsin G can all cleave
PAR2. Neutrophil elastase and cathepsin G were first considered
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FIGURE 3 | PAR2 N-terminus with major cleavage sites identified. N-terminus of human PAR2 (1–84). The residues in red denote the canonical tethered
ligand and a corresponding AP that is revealed by trypsin cleavage. The corresponding APs for each protease are indicated in the boxes. Gray shading
represents membrane.
to be deactivating proteases due to their ability to cleave down-
stream from the canonical trypsin site and thereby disarm PAR2
and attenuate trypsin-dependent Ca2+ signals (104). However, a
recent study suggests that these cleavage events may also induce
PAR2 signaling bias.
Elastase cleaves PAR2 between S68/V69 (38) (Figure 3). Treat-
ment of KNRK-PAR2 cells with elastase does not induce Ca2+ sig-
nals but does trigger PAR2-dependent ERK phosphorylation by a
pathway that involves Gα12/13-mediated activation of Rho kinase.
In contrast to trypsin, elastase does not trigger β-arrestin recruit-
ment or receptor internalization. A synthetic peptide correspond-
ing to a tethered ligand domain that would be revealed by elastase
(VLTGKLTTVFL-NH2) fails to mimic the action of elastase and
to activate ERK or to stimulate Ca2+ signals in KNRK-PAR2 cells,
suggesting that elastase could activate PAR2 by a mechanism that
does not require tethered ligand binding to the cleaved receptor.
Indeed, the elastase cleavage site is close to the first transmem-
brane domain of PAR2, which would suggest that a tethered ligand
mechanism is unlikely. Presumably, cleavage per se may allow PAR2
to adopt an active conformation that favors activation of certain
signaling pathways. Although the functional relevance of elastase
activation of PAR2 is uncertain, it may contribute to inflamma-
tory diseases in which this protease-receptor pair is involved. For
example, neutrophil elastase activity is elevated in patients with
ulcerative colitis as well as dextran sulfate sodium-induced colitis
in mice (107), and the elastase inhibitor serpin B1 (107) and PAR2
antagonism and deletion protect against colitis (108). Therefore,
it will be important to determine whether elastase triggers PAR2-
dependent inflammatory signaling in colonocytes or immune cells
that express PAR2.
Similar to elastase, neutrophil cathepsin G and proteinase-
3 both cleave PAR2 downstream of the canonical trypsin site
(cathepsin G: P65/S66 and proteinase-3 V62/D63) (38) (Figure 3).
However, neither cathepsin G nor proteinase-3 stimulate
PAR2-dependent Ca2+ signals or activate ERK phosphorylation or
receptor internalization (38). Although these proteases can disarm
PAR2 by removing the trypsin-exposed tethered ligand, it remains
to be determined whether they also induce biased signaling or
they act as antagonists for the receptor. The functional relevance
of PAR2 cleavage by cathepsin G and proteinase-3 is unknown.
Cathepsin S
Cathepsin S, a lysosome cysteine protease of the papain family,
is expressed by antigen-presenting cells, including macrophages,
microglial cells, B-lymphocytes, and dendritic cells, and con-
tributes to antigen presentation and adaptive immunity (109).
Inflammatory mediators promote cathepsin S secretion from
macrophages and microglial cells (66, 110), and there is increased
cathepsin S activity in inflamed tissues, including synovial fluid
from patients with rheumatoid arthritis (111) and colonic secre-
tions from mice with colitis (67). Cathepsin S is active at both
lysosomal acidic pH and extracellular pH (66), and may thus be
able to activate PARs. When administered into the colonic lumen
of wild-type mice to replicate the increased luminal cathepsin
S detected in mice with colitis, cathepsin S causes visceral pain
(67). This hyperalgesia is absent from PAR2 knockout mice, sug-
gesting that cathepsin S can activate PAR2. Current studies are
investigating whether cathepsin S can activate biased PAR2 signal-
ing and to determine the functional relevance of this process for
PAR2-mediated inflammation and pain.
PAR2 ACTIVATION BY SYNTHETIC LIGANDS
In addition to proteases, synthetic peptides that mimic the trypsin-
exposed tethered ligand can also activate PAR2. The hexapep-
tides SLIGRL-NH2 and SLIGKV-NH2 corresponding respectively
to the mouse and human trypsin-revealed tethered ligands for
PAR2 have been extensively used as tools to study PAR2 func-
tion despite their relatively low potency. Both peptides have been
shown to induce a Gαq-dependent increase in [Ca2+]i (26, 32,
94, 104, 112–114), ERK1/2 activation (62, 98, 115), as well as
β-arrestin recruitment and subsequent internalization (98, 112).
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The effect of SLIGRL-NH2 on cellular cAMP levels is contro-
versial. In rabbit smooth muscle cells, SLIGRL-NH2 decreases
forskolin-induced accumulation of cAMP in a pertussis toxin-
sensitive manner (114). On the other hand, in HEK293 cells and
human keratinocytes, SLIGRL-NH2 increases cAMP formation
(95, 116). In keratinocytes, SLIGRL-NH2 stimulates a pertussis
toxin-insensitive and cAMP/PKA-independent activation of Rho
kinase (95). Thus, activated PAR2 may trigger different G protein
pathways depending on the cellular context and the availability of
other components of the signaling complex.
Although these APs can cause robust PAR2 signaling, mutage-
nesis studies have highlighted that different residues within the
activating ligand domain may determine the preference of the
receptor to activate certain signaling pathways such as Ca2+ ver-
sus MAPK. These studies not only support the idea that PAR2
can initiate biased signaling, they also provide important infor-
mation on the mechanisms of PAR2 activation. Mutagenesis of rat
PAR2 has revealed that the first two residues (S37L38) from the AP
are critical for PAR2 activation. Both mutated PAR2 receptor with
substitution of these two residues to alanine and its corresponding
soluble peptide ligand (AAIGRL-NH2) exhibit little or no activ-
ity (117). Notably, a subsequent study found that another analog
peptide of SLIGRL-NH2, SLAAAA-NH2, also showed minimum
Ca2+ signaling activity but was able to induce ERK1/2 phospho-
rylation via a Rho-kinase-dependent mechanism (32). Although
the PAR2 binding pocket for APs has yet to be fully identified, the
importance of extracellular loop 2 in PAR2 activation by soluble
peptides has been studied, leading to the suggestion that the glu-
tamic acid residues (E232E233 in rat PAR2, and E232Q233 in human
PAR2) may interact with the basic arginine residue at position
5 of the AP. This residue is required for activity since mutation
of either receptor or the peptide results in loss of Ca2+ signal
(118). It will be important to examine whether distinct or over-
lapping clusters of residues of PAR2 are responsible for binding to
different regions of the AP, thereby triggering different signaling
events.
PAR2 ACTIVATION BY SMALL MOLECULES
Recent advances in our understanding of the structure-activity
relationships of various PAR2 ligands have facilitated the develop-
ment of small molecule PAR2 agonists, albeit of limited potencies.
The potential for these compounds to exhibit signaling bias has
not been fully investigated, since most studies have only examined
their ability to affect PAR2-dependent Ca2+ signals. AC-98170 is
a partial agonist of PAR2-dependent Ca2+ signaling (30% efficacy
of SLIGRL-NH2), but with a lower EC50 than AC-55541, another
small molecule agonist for PAR2 (119). Whether these compounds
are biased agonists of different PAR2 signaling pathways remains
to be investigated.
Small molecule PAR2 antagonists have also been developed.
One such compound, GB88, is a competitive antagonist for both
trypsin- and AP-induced Ca2+ signaling, although GB88 can selec-
tivity activate other PAR2-dependent pathways, including cAMP
formation, Rho-kinase stimulation, and ERK1/2 phosphorylation
(120). Thus, rather than acting as an antagonist for PAR2, GB88
may act as a biased agonist for this receptor. However, the antag-
onistic activity of GB88 is sufficient to attenuate PAR2-induced
paw edema and acute inflammation, as well as collagen-induced
arthritis in rats (121, 122), suggesting that relative contribu-
tion of PAR2 in these disease conditions might be primary via
Ca2+-dependent pathways.
Like GB88, K-14585 also has a complex pharmacology. In
human skin epithelial cells, K-14585 is able to block SLIGKV-
NH2-induced inositol phosphate accumulation and p38 MAPK
phosphorylation without affecting PAR2-mediated ERK1/2 acti-
vation (123). However, although not significant, K-14585 alone
does induce a modest IP3 formation. Moreover, at a higher con-
centration, K-14585 triggers PAR2-dependent p38 MAP kinase
phosphorylation (123). Taken together, K-14585 may actually act
as a PAR2 agonist with relatively low potency.
PAR3 ACTIVATION AND SIGNALING
Although thrombin cleaves PAR3 at K38/T39, there is little evidence
that the cleaved receptor is capable of signaling. Thrombin and a
synthetic peptide corresponding to the putative tethered ligand
failed to generate PAR3-dependent Ca2+ signals (19). However,
this PAR3-derived AP is able to activate PAR1 and PAR2 (72).
Instead of signaling in its own right, PAR3 appears to be a co-factor
for the activation of other PARs, including PAR4 and PAR1 (27,
29, 30). Co-expression of PAR3 with PAR4 in COS-7 cells leads to
over 10-fold increase in the efficiency of thrombin cleaving PAR4
compare to PAR4 expressed alone (EC50 from 0.3 to 0.05 nM) (29).
However, with the appreciation of PAR biased signaling, further
studies are warranted to examine the full repertoire of potential
PAR3 signals.
In contrast to other PARs, fewer proteases have been iden-
tified that can cleave PAR3. Besides thrombin, APC is the only
protease to be identified that exhibits proteolytic activity toward
PAR3 (27, 74). In immortalized human and mouse podocytes,
which have higher expression of PAR2 and PAR3 than PAR1
and PAR4, the maximum inhibitory effect of APC-dependent
podocyte apoptosis requires cleavage of N-terminal domain of
PAR3 by APC at the same position as thrombin (27). Cleav-
age of PAR3 by APC promotes dimerization between PAR2 and
PAR3, and this is required for APC-dependent cytoprotective
effect. A recent study reported a novel mechanism of APC acti-
vation of PAR3 via a cleavage at a non-canonical site (R41/G42 X
instead of K38/T39) (74). Peptide hydrolysis experiments revealed
a slow kinetics of APC cleavage of PAR3 (50% peptide cleav-
age reached after ~5 h), suggesting that other modulators may
facilitate APC cleaving PAR3 in cells; indeed, the efficiency of
this cleavage increased proportional to the expression of EPCR
(74). This novel cleavage by APC generates a new tethered lig-
and domain starting with G42APPNS. Consistent with a tethered
ligand activating mechanism, APC-AP (G42APPNSFEEFPFS54-
NH2) is able to prevent thrombin-induced endothelial bar-
rier disruption. Interestingly, an extended peptide generated
from thrombin cleavage site (40TFGAPPNSFEEFPFS54-NH2)
fails to do so. This suggests that APC and thrombin activa-
tion of PAR3 mediates different signaling profile, and thus is
involved in different cellular response, respectively. However,
similar to thrombin activation of PAR3, existence of another
receptor, such as PAR1 is necessary for APC/PAR3-mediated
signaling (74).
www.frontiersin.org May 2014 | Volume 5 | Article 67 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zhao et al. Protease-biased signaling
PAR4 ACTIVATION AND SIGNALING
PAR4 was identified by a homology search using amino acid query
sequence derived from known sequences of PAR1, PAR2, and PAR3
(20). The putative protease cleavage site was identified (R47/G48),
and the EC50 of thrombin toward PAR4 was much higher compare
to other thrombin sensitive receptors PAR1 and PAR3 (5 nM for
PAR4, and 0.2 nM for PAR1 and PAR3) (17, 19, 20). Further inves-
tigation suggests that this may be due to the lack of the thrombin
binding site within the amino terminus of the receptor. Consistent
with this observation, γ-thrombin, another isoform of throm-
bin that lacks a receptor binding site exhibits similar affinity on
PAR4 compare to α-thrombin (20). Different from other PARs
that can be cleaved preferentially by trypsin or thrombin, PAR4
exhibits similar sensitivity toward both enzymes. Both throm-
bin and trypsin activities toward PAR4 can be abolished by R47/A
mutation of the receptor, suggesting that both enzymes cleave the
receptor at the same site (20).
Compared to PAR1 and PAR2, little is known about biased
signaling of PAR4, and to date no additional activating cleav-
age sites have been identified. However, although proteases such
as plasmin can activate PAR4 by cleaving the receptor at the
canonical site, thrombin and plasmin cleave PAR4 with differ-
ent kinetics, possibility due to different mechanisms of action
or the affinity of the proteases for the receptor (20). In mouse
platelets, PAR3 binds to thrombin and thereby acts as a co-factor
to facilitate thrombin cleavage and activation of PAR4 (29). How-
ever, in both transfected cell lines as well as platelet, instead of
acting as a co-factor, the presence of PAR3 inhibits plasmin-
mediated PAR4 activation leading to a decrease in intracellular
Ca2+ mobilization and platelet aggregation (79). The mecha-
nism that underlies these findings is not clear. However, since
thrombin cleaves both PAR3 and PAR4 whereas plasmin can
only cleave PAR4, the conformation of the PAR3–PAR4 recep-
tor pair might be different after plasmin or thrombin cleavage.
In addition, difference in binding affinities and kinetics of plas-
min and thrombin for PAR4 may also result in distinct receptor-
protease complex formation and lead to variation in downstream
responses.
Cathepsin G is a neutrophil serine protease that plays an impor-
tant role in inflammation. Cathepsin G can evoke PAR4-dependent
Ca2+ signals in human platelets and in PAR4-transfected fibrob-
lasts (81). Cathepsin G and PAR4 are upregulated in ulcerative
colitis patients, and inhibition of cathepsin G and PAR4, but not
PAR1 or PAR2, is protective (124). Although no direct evidence
suggests that PAR4 is the target for cathepsin G in colitis, this
study highlights the possibility of targeting cathepsin G or PAR4
as novel therapeutic approach.
Recently, mannose-binding lectin-associated serine protease-1
has been shown to cleave PAR4 but not PAR1 or PAR2 in endothe-
lial cells, and to induce PAR4-dependent Ca2+ responses and
activation of NF-κB and p38 MAPK pathways. However, the exact
cleavage site remains to be determined (82).
SIGNALING BY PAR DIMERS
Although most studies have examined signaling by monomeric
PARs, considerable evidence suggests that PARs may form homo-
or hetero-dimers and function as a complex. Dimerized PARs
could adopt unique conformations and activate different signaling
pathways compare to monomer (125).
As a receptor that exhibits little or no activity when expressed
alone, PAR3 has been examined as a co-factor for other PARs. PAR3
can modulate the activity of PAR1 by potentiating its response
to thrombin, thereby increasing endothelial barrier permeability
without altering Ca2+ responses (30). This receptor dimer pair
favors coupling to Gα13 over Gαq, whereas both pathways are sim-
ilarly activated by PAR1 monomer (30). Thus, PAR1 may exhibit
distinct signaling profiles in response to the same ligand when
coupled to PAR3.
In mouse platelets, dimerization between PAR3 and PAR4 leads
to negative regulation of PAR4-mediated Ca2+ mobilization and
PKC activation without affecting Gα12/13 and Gαi activation, sug-
gesting that PAR4 signaling is biased away from Gαq activation
when coupled to PAR3 (126).
In human podocytes, APC cleavage of PAR3 leads to the for-
mation of PAR2 and PAR3 heterodimers, which is essential for
the anti-apoptotic actions of APC (127). Although the signaling
pathways that regulate this activity remain to be defined, the obser-
vation that both PAR2 and PAR3 activating peptides were able to
produce similar effects suggest that the formation of this hetero-
dimer may stimulate signaling pathways that are similar to those
activated by PAR2 monomers.
Another example of the contribution of receptor dimeriza-
tion to biased PAR signaling is dimerization between PAR1 and
PAR2. PAR1–PAR2 dimerization has been demonstrated in both
overexpression system and endogenous expression system (128,
129). When PAR1 forms dimer with PAR2, the thrombin-revealed
PAR1 tethered ligand can trans-activate PAR2 and trigger PAR2-
dependent Gαi/Rac signaling, while PAR1-mediated Gαq and
Gα12/13 signaling is switched off (130). In addition, recruitment
of β-arrestin to the PAR1–PAR2 dimer exhibits distinct kinetic
compared to each protomer, suggesting a potential alteration in
β-arrestin-dependent ERK1/2 signaling (128). During the early
development of sepsis, the effect of thrombin is vascular disrup-
tion whereas at the later phase of sepsis, with increasing expression
of PAR2, thrombin induces a vascular protective effect that is
mediated by PAR2/Rac1 activation (130).
Protease-activated receptors may act as co-factors or may
dimerize either constitutively or in a ligand-dependent manner.
The formation of dimers may play a role in organization of
receptors at the cell surface, and may allosterically modulate the
activation of either monomer or act as a complex that generates
unique signaling outcomes.
REGULATION OF PAR SIGNALING BY DIFFERENT G PROTEIN
COUPLING
Different proteases can lead to biased PARs activation, and PAR
signaling can also be modulated by co-factors and receptor dimer-
ization. In addition, the interaction of PARs with different G
proteins also has marked influence on the outcome of protease
signals. In response to a single protease, PARs are able to cou-
ple to multiple G proteins. Although how this occur is not clear,
recent studies using bioluminescence resonance energy transfer
(BRET) approach suggest dynamic regulation of PAR1 and PAR2
coupling with multiple G proteins. In Cos-7 cells, both receptors
Frontiers in Endocrinology | Molecular and Structural Endocrinology May 2014 | Volume 5 | Article 67 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zhao et al. Protease-biased signaling
spontaneously form pre-assembled complexes with Gαi, whereas
they only couple to Gα12 following ligand stimulation, and with
slow kinetics (131, 132). Further investigation revealed the exis-
tence of two different PAR populations that are responsible for
coupling to different Gα protein. The existence of distinct receptor
populations may be interpreted as receptor clustering in different
membrane microdomains such as membrane raft and caveolin-
containing vesicles (131). GPCRs located in lipid raft-enriched
domains may assure certain conformations of the receptor that
preferentially couple to specific G proteins compared to receptor
located in non-raft membrane compartment (133). It would be of
great interest to examine whether divergent PARs signaling in var-
ious cell types depends on the lipid component of the membrane
and whether altering membrane lipid composition leads to a shift
in PAR signaling profile, thereby contributing to bias signaling.
This mechanism may also account for the tissue specificity of PAR
signaling.
TERMINATION OF PAR BIASED SIGNALING
A growing number of proteases have been identified that can
cleave PARs at distinct sites, leading to diverse signals. One strik-
ing observation is the capacity of different proteases to stimulate
receptor endocytosis. It is well established that cleavage of PARs at
canonical activation site leads to rapid receptor internalization in
a β-arrestin-dependent (PAR2) or -independent (PAR1) manner
(96, 134). Receptor endocytosis not only contributes to signaling,
but is also the first step in the degradation of activated PARs, which
irrevocably terminates their ability to signal. Thus, if cleaved PARs
remain at the cell surface, how is signaling regulated?
PHOSPHORYLATION
Most information about the regulation of PARs has been derived
from studies of the canonical mechanisms of PAR activation. After
cleavage by thrombin or trypsin, both PAR1 and PAR2 are rapidly
phosphorylated by protein kinases, including GRKs, and second
messenger kinases such as PKA and PKC (135–137). Phospho-
rylation within the C-terminal tail of the receptor serves as the
primary mechanism to shut down G protein coupling and signal-
ing. PAR1 is phosphorylated by GRK3 in Xenopus laevis oocytes
and GRK5 in human endothelial cells (135, 137). Although the
specific GRKs that phosphorylate PAR2 in native systems have not
been identified, it is clear that PAR2 activation by trypsin recruits
multiple GRKs in overexpression system (138). In terms of selec-
tivity of certain GRKs over others, in endothelial cells GRK5 is the
critical isoform that mediates thrombin-induced desensitization
of PAR1 (137). GRK5 overexpression inhibits thrombin-induced
Ca2+ signaling whereas GRK3 and GRK6 have no such effect
(137). Whether proteases that cleave PARs at other sites also
induce GRK recruitment and differential receptor phosphoryla-
tion remains to be determined. However, given the inability of
many of these alternatively cleaved receptors to recruit arrestins,
alterations in receptor phosphorylation are likely to occur. Studies
of other GPCRs, such as β-adrenergic receptors (139) and opioid
receptors (140), suggest that receptor phosphorylation occurs in
an agonist-selective manner. For example, different biased ago-
nists for β-adrenergic receptor trigger distinct patterns of recep-
tor phosphorylation by different GRKs, which may establish a
“barcode” that determines β-arrestin recruitment and functional
responses (139). Whether this is also the case for PARs remains to
be explored.
Phosphorylation of GPCRs often leads to β-arrestin recruit-
ment and receptor internalization. However, this is not always the
case. The morphine-activated µ-opioid receptor is phosphory-
lated by GRK5 at Ser375, which is sufficient for receptor desensiti-
zation but not β-arrestin recruitment or receptor internalization.
On the other hand, DAMGO, another agonist for the same recep-
tor, leads to phosphorylation at both Ser375 and Thr370, which
leads to both receptor desensitization and internalization (141).
Thus, biased proteases signaling might be terminated by phos-
phorylation without necessary internalization. It will be of interest
to determine whether different proteases induce specific patterns
of receptor phosphorylation, and to determine the functional
relevance of these events.
INTRACELLULAR TRAFFICKING AND SIGNALING
β-Arrestins not only act as chaperone proteins that direct receptor
trafficking, but also are active participants of signaling by internal-
ized receptors. β-arrestins mediate multiple steps of PAR signaling,
including PAR1-mediated Akt activation, and PAR1 and PAR2-
dependent ERK1/2 activation (96). After activation by trypsin,
PAR2 stably couples to β-arrestin and together they co-translocate
to early endosomes where they generate a second wave of intracel-
lular signals (96). As an important scaffolding protein, β-arrestin
is essential for the formation of the signaling complex includ-
ing PAR2-Raf1 and activated ERK. This complex will ensure the
appropriate subcellular localization of PAR2-mediated ERK activ-
ity. Thus, the stability between activated receptor and β-arrestin is
essential for determining the duration of this activation. It has been
pointed out that PAR2 may induce distinct cellular response from
Gαq pathway via a β-arrestin-mediated mechanism (96, 142, 143).
However, proteases such as elastase and cathepsin S are unable
to induce β-arrestin recruitment, suggesting their lack of ability
to further promote β-arrestin-dependent signals. In contrast to
PAR2, where both β-arrestins have similar effects, PAR1-mediated
Akt signaling is differentially mediated by different β-arrestins,
depending on the mechanism of proteolytic activation. For exam-
ple, β-arrestin 1 is required for rapid activation of Akt induced by
thrombin, whereas APC cleavage leads to β-arrestin 2-dependent
Akt activation (53, 134, 144). Although the underlying mechanism
is not established, it may relate to different receptor conformations.
Besides desensitization, receptor trafficking to different subcel-
lular compartments also plays an important part in regulation of
GPCR signaling. For both PAR1 and PAR2, activation by trypsin
or thrombin leads to receptor trafficking to endosomes, followed
by lysosome sorting and receptor down-regulation. (145). How-
ever, many proteases such as elastase and APC failed to induce
PARs endocytosis. The regulatory machinery for biased protease-
signaling remains unknown. The potential involvement of com-
partmentalization and redistribution of the receptors to mem-
brane subdomains seems to be an attractive area to explore. As
mentioned earlier, APC-induced PAR1 signals require localiza-
tion of the signalosome to caveolae, a specific lipid rich plasma
membrane microdomain. Caveolae has also been suggested to
be involved in TF-mediated PAR2 signaling. In breast carcinoma
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cells, both TF and PAR2 are observed co-localized in cholesterol-
rich caveolae, and depletion or sequestration of plasma membrane
cholesterol significantly impaired TF-VII1 induced cell signaling
(146). It would be interesting to see if different proteases prefer tar-
geting PARs at certain membrane microdomains or there is PARs
redistribution upon activation by different proteases.
TRANSLATIONAL RELEVANCE OF PROTEASE-BIASED
SIGNALING OF PARs
The contribution of PARs to important patho-physiological
processes, including hemostasis, inflammation, pain, and pro-
liferation, has been extensively investigated through studies of
PAR-deficient mice and by use of proteases and synthetic ago-
nists/antagonists of the canonical signaling pathways (21, 22). The
capacity of certain proteases to acts as biased PAR agonists or even
antagonists adds further complexity to this system, and the rele-
vance of protease-biased signals to complex patho-physiological
processes is far from clear. A major difficulty relates to the identities
of the proteases that activate PARs under physiological condi-
tions and during disease. Since proteases are regulated through
post-translational control of activity (e.g., by zymogen processing
and endogenous inhibitors), studies should include assessment
of enzymatic activity rather than gene or protein expression. A
major advance in this regard is the use of activity-based probes
that covalently interact with activated proteases, allowing their
localization by whole animal or cellular imaging and identifica-
tion by proteomic approaches (99). This approach has been used
to detect activated cathepsin S in macrophages of tumors and
the inflamed colon, as well as in spinal microglial cells during
colitis (67, 147). However, the use of probes is likely to reveal
that multiple proteases become activated during physiological and
pathological events, many of which could activate or disarm PARs.
Additional information can be provided by studies of protease
knockout mice or through use of selective inhibitors. However, a
detailed understanding of the importance of biased signaling of
PARs would probably require genetic or pharmacological strate-
gies to selectively disrupt particular biased pathways, and such
tools are currently lacking.
Although the patho-physiological importance of biased signal-
ing of PARs is not fully understood, biased agonism could explain
certain paradoxes about the patho-physiological contribution of
PARs. For example, PARs can have both pro-inflammatory and
anti-inflammatory roles, which may depend on the animal mod-
els, species, tissues, or the protease that drive the response. In an
ovalbumin-induced model of allergic inflammation of the mouse
airway, PAR2 deletion is protective, suggesting that PAR2 con-
tributes to the development of immunity and to allergic inflamma-
tion of the airway (148). However, in a lipopolysaccharide-induced
pulmonary neutrophilia model, PAR2 shows a protective effect
(149, 150). The underlying mechanism of these observed differ-
ences is unclear. However, differences in the repertoire of proteases
that are activated in acute versus chronic inflammation, leading to
distinct mechanisms of PAR signaling, could be one explanation.
Lipopolysaccharide-induced pulmonary neutrophilia is an acute
inflammation characterized by influx of neutrophils and activa-
tion of elastase and proteinases 3, biased agonists of PAR1 and
PAR2. On the other hand, ovalbumin-induced inflammation is
characterized by infiltration of eosinophil and macrophages, lead-
ing to activation of distinct proteases (151). Thus, the predominant
active proteases for PAR2 may be different in these two models,
which could potentially activate different signaling pathways that
lead to opposite responses. The contrasting pro-inflammatory and
cytoprotective actions of thrombin and APC, respectively, may also
be attributed to PAR1 biased signaling. In this instance, the rela-
tive concentration of the proteases as well as the occupancy of
EPCR by its ligand are critical in determining the PAR1 signaling
pathways (28).
CONCLUSION AND FUTURE DIRECTIONS
Considerable progress has been made in defining the mecha-
nisms by which proteases and synthetic agonists activate PARs.
Proteases, peptides, and small molecules have been identified
that can activate PARs by distinct mechanisms, leading to the
stimulation of divergent pathways of receptor signaling and traf-
ficking. The information derived from these studies has provided
insights into the signaling pathways that are responsible for certain
patho-physiological processes.
However, there are many unanswered questions about biased
signaling of PARs. The ability of a PAR cleaved by different pro-
teases or bound to various synthetic agonists to differentially signal
probably arises from distinct receptor conformations. However,
the structures of PARs in these different stabilized states remain to
be determined. Although some proteases activate PARs by expo-
sure of a tethered ligand, this is not always the case and the
mechanism by which proteolysis per se can activate signaling is
unknown. There is tantalizing evidence to suggest that biased
signaling may underlie contrasting patho-physiological conse-
quences of PAR activation, depending on the available proteases
and the nature of PAR signaling. However, the proteases that are
responsible for PAR activation in particular cell types in different
conditions remain to be identified, and the signaling pathways that
give rise to particular patho-physiological outcomes are not fully
defined. Finally, very little is known about the mechanisms that
regulate protease-biased signaling of PARs, particularly by those
proteases that fail to promote the recruitment of β-arrestins and
endocytosis of the activated receptors.
Whether protease-biased signaling of PARs can be exploited
therapeutically remains an open question. The development
of receptor antagonists or agonists that target disease-relevant
PAR signaling pathways without affecting beneficial signaling
events could provide a route for enhanced selectivity, with fewer
on target side-effects. Future challenges will be to identify the
primary pathways that mediate PAR-dependent physiological
and patho-physiological events, and to develop receptor ago-
nists and antagonists that selectively target these pathways. A
deeper understanding of the mechanisms of initiation, regula-
tion, and termination of protease-signaling will have profound
implication in developing therapeutics for many critical con-
ditions, including sepsis, thrombosis, inflammation, and pain
processes.
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